Tech Company Financing Transactions
Sparrow Pharmaceuticals Funding Round
Sparrow Pharmaceuticals closed a $50 million Series A investment round on 5/19/2021. Backers included OrbiMed, RiverVest Venture Partners and U.S. Venture Partners.
Transaction Overview
Company Name
Announced On
5/19/2021
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Investors
Proceeds Purpose
This financing will allow the company to accelerate the development of its proprietary oral HSD-1 inhibitor, SPI-62, which targets the source of steroids that cause toxicity in key tissues.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
920 SW 6th Ave. 1200
Portland, OR 97204
USA
Portland, OR 97204
USA
Phone
Website
Email Address
Overview
Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess. We are developing novel therapies to address the key limitations of treatments for endogenous Cushing's syndrome (Cushing's), autonomous cortisol secretion (ACS), and polymyalgia rheumatica (PMR).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Jacks
Chief Scientific Officer
David Katz
Vice President
Jeffrey Drajesk
Browse more venture capital transactions:
Prev: 5/19/2021: Amount venture capital transaction
Next: 5/19/2021: Vise venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs